BIO-RAD LABORATORIES-A (BIO) Fundamental Analysis & Valuation
NYSE:BIO • US0905722072
261.82 USD
-8.07 (-2.99%)
At close: Mar 12, 2026
261.82 USD
0 (0%)
After Hours: 3/12/2026, 6:40:00 PM
This BIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Overall BIO gets a fundamental rating of 5 out of 10. We evaluated BIO against 57 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. BIO Profitability Analysis
1.1 Basic Checks
- In the past year BIO was profitable.
- BIO had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
- Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
- BIO has a Return On Assets of 7.18%. This is amongst the best in the industry. BIO outperforms 84.21% of its industry peers.
- With a decent Return On Equity value of 10.20%, BIO is doing good in the industry, outperforming 78.95% of the companies in the same industry.
- The Return On Invested Capital of BIO (2.02%) is better than 61.40% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 11.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROIC | 2.02% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
1.3 Margins
- BIO has a better Profit Margin (29.42%) than 96.49% of its industry peers.
- BIO's Profit Margin has declined in the last couple of years.
- BIO has a better Operating Margin (10.30%) than 70.18% of its industry peers.
- BIO's Operating Margin has declined in the last couple of years.
- The Gross Margin of BIO (52.01%) is better than 61.40% of its industry peers.
- BIO's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% |
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
2. BIO Health Analysis
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for BIO has been reduced compared to 1 year ago.
- BIO has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, BIO has an improved debt to assets ratio.
2.2 Solvency
- BIO has an Altman-Z score of 3.08. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- BIO has a better Altman-Z score (3.08) than 66.67% of its industry peers.
- The Debt to FCF ratio of BIO is 3.21, which is a good value as it means it would take BIO, 3.21 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of BIO (3.21) is better than 82.46% of its industry peers.
- BIO has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- BIO's Debt to Equity ratio of 0.16 is in line compared to the rest of the industry. BIO outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 3.08 |
ROIC/WACC0.19
WACC10.56%
2.3 Liquidity
- BIO has a Current Ratio of 5.62. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of BIO (5.62) is better than 82.46% of its industry peers.
- A Quick Ratio of 4.19 indicates that BIO has no problem at all paying its short term obligations.
- BIO has a better Quick ratio (4.19) than 75.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 |
3. BIO Growth Analysis
3.1 Past
- BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- The Earnings Per Share has been decreasing by -1.19% on average over the past years.
- BIO shows a small growth in Revenue. In the last year, the Revenue has grown by 0.65%.
- The Revenue has been growing slightly by 0.29% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
3.2 Future
- The Earnings Per Share is expected to grow by 0.58% on average over the next years.
- Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 2.54% on average per year.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BIO Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 26.39, BIO can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 66.67% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (25.71), we can say BIO is valued inline with the index average.
- BIO is valuated quite expensively with a Price/Forward Earnings ratio of 25.24.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 66.67% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.82. BIO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.39 | ||
| Fwd PE | 25.24 |
4.2 Price Multiples
- 82.46% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.86 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.77
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%
5. BIO Dividend Analysis
5.1 Amount
- BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO Fundamentals: All Metrics, Ratios and Statistics
261.82
-8.07 (-2.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners90.44%
Inst Owner Change-2.09%
Ins Owners8.17%
Ins Owner Change0%
Market Cap7.07B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target341.7 (30.51%)
Short Float %5.19%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-5.63%
PT rev (3m)-5.63%
EPS NQ rev (1m)-20.96%
EPS NQ rev (3m)-21.27%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)-2.46%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.39 | ||
| Fwd PE | 25.24 | ||
| P/S | 2.74 | ||
| P/FCF | 18.86 | ||
| P/OCF | 13.28 | ||
| P/B | 0.95 | ||
| P/tB | 1.05 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.79%
EPS(NY)10.37
Fwd EY3.96%
FCF(TTM)13.88
FCFY5.3%
OCF(TTM)19.72
OCFY7.53%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)5.77
PEG (5Y)N/A
Graham Number248.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROCE | 2.65% | ||
| ROIC | 2.02% | ||
| ROICexc | 2.38% | ||
| ROICexgc | 2.62% | ||
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% | ||
| FCFM | 14.5% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.1% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 49.3% | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 | ||
| Altman-Z | 3.08 |
F-Score5
WACC10.56%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 5 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 4.57% in the next year.